One way to overcome the inadequate T-cell infiltration due to a lack of tumor immunogenicity is supplying the patient with T-cells that target the antigens with low immunogenic potential, and this is possible by generating, ex vivo, a large amount of CD8+ T-cells designated to target a specific tumor antigen, such as NY-ESO-1 in sarcoma and MART-1 in melanoma, through adoptive cell therapy (ACT). Here, CD8A is linked to neoplasm.